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Overactive bladder syndrome (OAB) is a highly prevalent urinary dysfunction, with considerable economic and human costs.
Clinical diagnosis of OAB is still based on subjective symptoms. A new accurate, objective and noninvasive test to diagnose
OAB and assess therapeutic outcome is lacking. Recent studies in lower urinary tract (LUT) dysfunctions, particularly in OAB
patients, indicate that urinary proteins (neurotrophins, prostaglandins, and cytokines), serum C reactive protein, and detrusor
wall thickness are altered, and such changes could be used as biomarkers of the disease. Nowadays, increasing emphasis has been
given to the role of urinary neurotrophins, namely nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF),
as key players in some urinary dysfunctions. Although recently considered to be a bladder dysfunction biomarker, urinary NGF
presents low sensitivity and speciﬁcity. Preliminary results suggest that BDNF may serve as a more eﬃcient biomarker. Even
though we have to wait for future studies to conﬁrm the potential role of NGF and BDNF as OAB biomarkers, it is already clear
that neurotrophins will contribute to elucidate the physiopathological basis of OAB. Herein are reviewed the latest advances in this
new and exciting ﬁeld, the detection and clinical application of emerging OAB biomarkers.
1.Introduction
OAB is currently recognized as a chronic disorder with an
overall prevalence in the adult population of above 10%, but
that may exceed 40% in elderly groups [1]. According to the
International Continence Society (ICS), OAB is deﬁned as a
clinical syndrome characterized by the presence of urgency,
with or without urgency incontinence, usually accompanied
by daytime frequency and nocturia, in the absence of
proven infection or other obvious pathology [2, 3]. Urinary
urgency, deﬁned as a sudden compelling desire to void
that is diﬃcult to defer, is the unique symptom that must
be present in order to establish the diagnosis of OAB [3].
However, urgency is diﬃcult to be understood by patients
and caregivers. Diﬀerentiation between urgency and urge
is not always straightforward. Yet, urge is a normal bladder
sensation, gradual in appearance, usually proportional to the
degree of bladder ﬁlling, and that can be easily controlled by
individuals.Inaddition,gradingurinaryurgencyisadiﬃcult
task, which may render diﬃcult the eﬃcacy of a therapy.
The multiple questionnaires available to quantify and grade
urgency severity (USS, OABq) reﬂect this problem [4, 5].
One way to overcome this problem would be the
introduction of an objective test for the diagnosis of OAB.
During the last few years, several attempts have been made,
though with limited success. Detrusor overactivity (DO) is
the urodynamic hallmark of OAB. Nevertheless, this abnor-
mality can only be identiﬁed in half of the patients, whereas
normal individuals often have asymptomatic involuntary
detrusor contractions [6]. In addition, urodynamics is an
invasive test. These facts decrease the role of this test as a
useful tool for OAB diagnosis.2 Advances in Urology
Another potential marker for OAB is detrusor wall
thickness (DWT), determined by ultrasound. In patients
with OAB, it has been hypothesized that frequent detrusor
contractions during bladder ﬁlling result in tetanic detrusor
motions and cause muscular hypertrophy. DWT is shown
to be higher in OAB patients and to decrease in response
to antimuscarinic treatment [7], suggesting that DWT mea-
surement is a useful biomarker to monitor disease progres-
sion and therapeutic eﬃcacy. However, DWT measurement
may not be reproducible. Liu et al. determined DWT in
normal subjects and patients with OAB dry, OAB wet and
interstitial cystitis (IC). Wide variation was found among all
groups. There was a trend to a higher DWT in patients with
OAB, whether dry or wet, compared with normal controls
and patients with IC. However, the diﬀerence was not statis-
tical signiﬁcant [7]. A recent study compared measurement
of DWT by transvaginal and transabdominal ultrasound. No
signiﬁcant diﬀerence of transvaginal ultrasound measured
DWT was noted among women with OAB dry, OAB wet,
and normal controls. Inversely, transabdominally measured
DWT, at bladder capacity, was signiﬁcantly higher in women
with OAB wet or DO [8]. Until now, studies are contradic-
tory about the potential value of DWT as a diagnostic tool
for OAB [9]. Similar problems have been detected with DWT
measurement in patients with bladder outlet obstruction
(BOO). Various studies showed an increase in DWT with
increasing the degree of BOO and a predictive value of
DWT in the diagnosis of BOO [10, 11]. In contrast, in a
recent investigation, DWT was remarkably uniform whether
patients had a normal urodynamic test, BOO, or DO [8].
The diﬀerences in the values of DWT obtained in various
studies may be explained by the use of diﬀerent ultrasound
probes, with diﬀerent frequencies, as well as in the resolution
of ultrasound-generated images [8].
Recently, near-infrared spectroscopy (NIRS), an optical
technology, has also been studied as a potential noninvasive,
diagnostic tool for DO in OAB patients. NIRS detects the
hemodynamic variations in tissues by the use of noninvasive
measurements of changes in the concentration of tissue
chromophores, such as oxyhemoglobin (O2Hb) and deoxy-
hemoglobin (HHb). Involuntary bladder contractions may
cause changes detectable by NIRS [12]. Until now, its value
to detect DO in clinical practice needs to be conﬁrmed.
Taking into account the previous data, new simple,
noninvasive tests to diagnose OAB and assess therapeutic
outcome are eagerly needed. Some recent studies have
focused on this new and exciting ﬁeld, the detection and
clinical application of OAB biomarkers.
2. Neurotrophins
Nowadays, increasing attention is given to the role of neu-
rotrophins, namely, nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) in OAB. Neurotrophins
are growth factors required by neuronal cells for diﬀeren-
tiation, survival, and maintenance, with a broad range of
activities in the central and peripheral nervous system either
in the developing or in the adult mammal [13]. It has been
suggested that NGF and BDNF are released from urothelial
and detrusor smooth muscle cells. These neurotrophins act
by binding to high-aﬃnity receptors TrkA (for NGF) and
TrkB (for BDNF), cell-surface transmembrane glycoproteins
expressed in bladder urothelial cells, and primary aﬀerents
[13–15].
Low-aﬃnity receptors, such as the p75, may also play an
important role on neurotrophins eﬀects, but this aspect is
still poorly studied.
2.1. Urinary Nerve Growth Factor. NGF was the ﬁrst neu-
rotrophin to be discovered, by Rita Levi-Montalcini, in the
1950s [16]. It may be synthesized by both neuronal and
nonneuronal cells and plays an essential role during the
developmentoftheperipheralnervoussystem,regulatingthe
survivalandfunctionofpostganglionicsympatheticneurons
andsmall-diameterprimaryaﬀerents[17–20].Uponbinding
to TrkA, NGF may induce the expression of several genes
codingforvariousneurotransmitters,receptors,andvoltage-
gated ion channels [17]. In addition to TrkA, NGF binds to
p75, a low-aﬃnity pan-neurotrophic receptor also expressed
in bladder urothelial cells and primary aﬀerent nerves.
Several clinical and experimental data have suggested an
interesting link between increased levels of NGF, either
in bladder tissue or urine, and DO, and OAB [21]. In
animal models, NGF is released in high amounts from
smooth muscle cells and urothelium of overactive bladders
[14]. In addition, recent studies have revealed that acute
and chronic local administration of NGF reduces bladder
capacity and intercontraction interval and increases bladder
reﬂex contractions [22–25]. Likewise, TrkA blockade or
NGF sequestration decreases the high frequency of bladder
contractions in animal models of bladder inﬂammation [26]
and spinal cord transection [27, 28]. Interestingly, TRPV1
seems to be an essential downstream receptor for NGF
activity in the bladder. TRPV1 knockout mice, in contrast
with wild-type littermates, do not develop DO, in spite of
exogenous NGF administration [26]. Also, NGF increases
TRPV1 translation and activity [29]. This crosstalk between
NGF and TRP family should be further investigated in the
future.
2.1.1. Urinary NGF Levels in OAB Patients. Similarly to what
happens in experimental studies, in humans, it has also
been postulated that increased levels of NGF in urine could
sensitize bladder aﬀerent pathways and enhance bladder sen-
sory input arriving to the central nervous system, eventually
leading to DO. Supporting this hypothesis, increased levels
of NGF have been found in the urine of patients with OAB,
idiopathic and neurogenic DO, IC, and BOO [30–36].
Recent pilot clinical studies have shown that urinary
NGF levels are signiﬁcantly higher (approximately 12-fold)
in patients with OAB than in normal controls [37–40].
UrinaryNGFconcentrationshavebeenfoundtobeincreased
in patients with OAB, particularly in those complaining of
urgency urinary incontinence (OAB wet) [39, 40]. Interest-
ingly, it has also been found that urinary NGF concentration
in OAB patients seems to correlate with urgency intensity.
Liu and coworkers reported on that patients classiﬁed as
havingmodiﬁedIndevusUrgencySeverityScale(USS)scoresAdvances in Urology 3
of 3 or 4 had signiﬁcantly higher NGF levels than those with
as c o r eo f2o rl o w e r[ 40].
The sensitivity and speciﬁcity was recently evaluated.
Using a urinary NGF/creatinine ratio >0.05, Chen and Kuo
found that the sensitivity and speciﬁcity of this test in the
diagnosis of OAB was 67.9% and 93.8%, respectively [41].
In spite of being a small study, recently, Antunes-Lopes
et al. found lower values of sensitivity and speciﬁcity for
NGF/creatinine ratio (>200pg/mg), with an area under the
curve in receiver-operator characteristics (ROCs) analysis
of 0.68 (Figure 1)[ 42]. In this study, there was a trend to
higher NGF/creatinine ratio in OAB patients compared to
healthy volunteers, but the diﬀerence did not reach statistical
signiﬁcance [42]. Moreover, surprisingly, in OAB patients
with high urinary concentration of NGF, Birder and co-
workers did not ﬁnd similar increases in bladder samples
obtained from the same group of patients [43]. More studies
are missing to clarify this puzzling discrepancy.
2.1.2. Urinary NGF as a Marker of Response to OAB Treat-
ment? Antimuscarinic treatment was shown to diminish
urinary NGF levels in parallel to the reduction of the USS
score, with the reversal occurring upon withdrawal of the
therapy [44, 45]. Also, in patients with intractable idiopathic
and neurogenic DO, detrusor injection of onabotulinum
toxin A has been shown to reduce urinary NGF levels [46].
According to these data, urinary NGF level could be used as
a tool to monitor the therapeutic eﬀect of antimuscarinics
and detrusor BoNT-A injection in OAB. However, as these
studies were not placebo controlled, some caution should be
taken in the results interpretation.
2.2. Urinary Brain-Derived Neurotrophic Factor. BDNF is the
most abundant neurotrophin in the human body, although
our knowledge about its role in normal and pathological
conditions is still very limited [47]. Like NGF, BDNF
also contributes to the survival and normal function of
sensory neurons [48–51]. BDNF is constitutively expressed
by small and medium-sized peptidergic neurons, but it is
also produced by nonneuronal cells [52, 53]. Besides its well-
establishedtrophiceﬀectonneuronaltissueanditsrelevance
in plasticity events, the importance of BDNF in nociception
has also been established [54]. BDNF is present in the spinal
cord, in terminal endings of sensory ﬁbres, colocalizing with
substance P and CGRP [55]. Interestingly, its expression may
be regulated by NGF [17].
2.2.1. BDNF in Lower Urinary Tract Dysfunctions. Little is
known about the role of BDNF in bladder function, both in
normal and in pathological conditions, and available studies
are mostly conﬁned to experimental models of bladder
dysfunction. It has been demonstrated that after chronic
bladder inﬂammation or spinal cord injury, the synthesis
of BDNF in the urinary bladder is strongly increased
[56–58]. A recent study showed that BDNF sequestration
improved bladder function in rats with chronic cystitis
[59]. Nevertheless, BDNF sequestration did not produce any
eﬀects on bladder reﬂex activity of intact animals, suggesting
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Figure 1: Receiver-operator characteristic (ROC) curves of urinary
NGF/creatinine and urinary BDNF/creatinine in OAB patients.
Notice that, for this cohort, BDNF has a better AUC than NGF.
that BDNF eﬀect on bladder function is relevant only in
pathological conditions.
In a recent study, Antunes-Lopes et al. assessed uri-
nary levels of BDNF in a population of adult healthy
volunteers (20 females and 20 males) to investigate if
there was a physiological pattern of secretion and if there
were diﬀerences between genders. In healthy volunteers,
BDNF/creatinine ratio (pg/mg) was systematically low, irre-
spective of gender or time of urine sampling. In contrast,
urinary BDNF/creatinine ratio was signiﬁcantly higher in
OAB patients compared to controls (Figure 2)[ 60].
Auspiciously, the striking diﬀerences found in this pre-
liminary observational study between OAB patients and
controls suggest that urinary BDNF may serve as a potential
biomarker of OAB syndrome. Using ROC analysis, the
area under the curve of urinary BDNF (Figure 1)s e e m st o
support this hypothesis, but further studies, involving other
centers, are necessary before a solid statement can be created
[60].
In addition to OAB, urinary BDNF was newly evaluated
in the urine of bladder pain syndrome/IC patients. The
urinary concentration was high at baseline and signiﬁcantly
reduced after botulinum toxin administration to the bladder
trigone [35]. A positive correlation could be established
between BDNF decrease and LUTS improvement [35].
2.3.NeurotrophinsandIntracellularPathways:TargetsforNew
Therapies? The study of urinary NT in patients with OAB
hasprovidednewinsightstotheunderlyingphysiopathology
of this disorder. Inﬂammation in the urinary tract can cause
an elevation of the urinary NGF level. Therefore, it can
be suggested that OAB is an inﬂammatory disorder of the
bladder [21]. NGF excretion is increased during bladder4 Advances in Urology
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Figure 2: BDNF/creatinine in the urine of female healthy volun-
teers and OAB patients, at baseline and after 3 months of lifestyle
intervention.
distension[36]althoughurinaryNGFlevelswereaugmented
in patients with OAB, whether the urine was collected from
an empty or a full distended bladder [61]. Although urinary
NGF increases signiﬁcantly in normal controls when they
refer a strong desire to void NGF levels were signiﬁcantly
lower than in patients with OAB at ﬁrst sensation of ﬁlling
[61]. These results suggest that urinary NGF level increases
physiologically in normal controls at strong desire to void,
butraisespathologicallyinpatientswithOAB[61].Although
the precise mechanisms by which urinary NGF promotes
DO and OAB are not yet deﬁned, neurotrophins are
known to inﬂuence expression and activity of receptors that
modulate bladder function, like P2X3 and TRPV1 receptors.
Cruz et al. showed that the latter is, in fact, essential
for NGF-mediated DO [29]. This ﬁnding is important to
envisage an eﬀective strategy to counteract the consequences
of high urinary NGF, levels in patients with DO [29].
In addition, neurotrophins activate intracellular signalling
pathways important for micturition control, as the MAPK-
ERK pathway. Some new molecules that are able to sequester
NGF and other neurotrophins (e.g., BDNF) have already
beentestedwithsuccessinpreclinicalmodelsofDO[59,62].
In the future, it is likely that Trk antagonists or neurotrophin
sequestering proteins may be eventually useful and eﬀective
treatments to control DO and OAB symptoms.
3.Prostaglandins
Prostaglandins (PGs) regulate LUT function. PGs are locally
synthesized in the bladder muscle and urothelium and
triggered by detrusor muscle stretch, bladder nerve stimu-
lation, bladder mucosa damage, and inﬂammation [63]. PGs
seem to contribute to the basal ton of the detrusor and to
modulate the activity of bladder nerves. PGs are involved
in micturition reﬂex by decreasing thresholds of the stimuli
necessary to trigger bladder contraction through activation
of the capsaicin-sensitive aﬀerent nerves. Therefore, PGs can
be related to bladder storage symptoms in patients with
OAB [63]. In an experimental study in rats, intravesical
instillation of PGE2 induced detrusor contraction, while its
topical application to the urethra caused urethral relaxation
[64]. Activation of prostaglandin EP3 receptors exerts an
excitatory eﬀect on urinary bladder function through mod-
ulation of bladder aﬀerent pathways [65].
At a clinical level, Kim et al. found that urinary levels
of PGE2 and PGF2α in patients with OAB were signiﬁcantly
increased compared to a control group [63]. In addition, an
inverse correlation was found between urinary PGE2 and the
volume to ﬁrst desire to void and the maximum cystometric
capacity [63]. On the other hand, Liu et al. measured urinary
levels of PGE2 in patients with OAB wet, OAB dry, IC, and
controls and did not ﬁnd signiﬁcant diﬀerences between the
subgroups [66].
In summary, the role of urinary PGs in the diagnosis
of OAB is still controversial and needs further investiga-
tion. Moreover, nonsteroidal anti-inﬂammatory drugs have
shown little eﬃcacy in treating OAB. A new alternative may
be the blockade of PGEreceptors. Moleculeslike ONO-8539,
a PGE2 receptor subtype EP1 antagonist, entered recently in
a phase 1 study [67] ,b u ti ti ss t i l lt o os o o nt om a k ec l e a r
statements about their therapeutic potential.
4.UrineCytokinesandUrineand
SerumC-ReactiveProtein
It has been hypothesized that OAB may be an inﬂammatory
process of the bladder [68]. Supporting this theory, recent
studies reported histological evidence of inﬂammation in
bladder specimens from OAB patients [69, 70]. However,
the biopsy-based conﬁrmation of bladder inﬂammation in
OAB requires an invasive and expensive procedure not
exempted of morbidity. Alternatively, cytokines may rep-
resent a biomarker considering that they are elevated in
biologic ﬂuids during inﬂammation. In the particular case of
OAB, Tyagi et al. analyzed the urine from OAB patients for
selected cytokines, chemokines, growth factors, and soluble
receptors. Their study revealed an elevation of several of
these putative biomarkers in the urine of OAB patients (P<
.05) [68]. Monocyte chemotactic protein-1 (MCP-1) and
soluble fraction of the CD40 ligand (sCD40L) were increased
more than tenfold over controls in the urine of OAB
patients [68]. At least ﬁvefold elevations were detected in the
urinary levels of macrophage inﬂammatory protein (MIP-
1β), IL-12p70/p40, IL-5, epidermal growth factor (EGF),
and growth-related oncogene (GRO-α) in OAB patients
compared to controls [68]. Finally, it was also noticed a
threefold elevation in the urine levels of sIL-2Rα and IL-10
in the OAB group [68].
C-reactive protein (CRP) is a widely studied general
marker of inﬂammation and infection. Its serum levels rise
dramatically during inﬂammatory conditions and are used
to determine disease progression or treatment eﬀectiveness.
Chuang et al. undertook a study to examine CRP levels
serum, urine, and bladder tissue of OAB dry and OAB
wet patients [71]. Signiﬁcantly higher serum CRP levels
were measured in OAB patients compared to controls [71].
Interestingly, higher values were noted in OAB wet than in
OAB dry [71].Advances in Urology 5
In what concerns urinary levels, the same study showed
that urinary CRP was barely detectable and the mRNA
expression of CRP in bladder biopsies was very modest [71].
Consequently, urinary and bladder CRPs seem to be much
lower than serum CRP levels, and current available methods
fordetectingCRPmightnotbesensitiveenoughtodevelopa
urinary assay. On the other hand, it should be reminded that
serum CRP level in patients with LUT symptoms may not
speciﬁcally reﬂect the condition of the LUT, as its levels are
inﬂuenced by any systemic inﬂammatory condition [71, 72].
So, at this moment, the importance of CRP as an OAB
biomarker seems rather modest.
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